Educational Administration: Theory and Practice
2024, 30(2), 1364-1372
ISSN: 2148-2403
https://kuey.net/

Research Article

A Comprehensive Review: Molecular Target And Procurable Treatment For Rheumatoid Arthritis

Swarnika Sharma[1], Umesh Kumar[1*], Ashok Kumar[1], Yash Pratap Singh[1], Jonny Kumar[1], Vishesh Panwar[2], Anuradha [3]

[1]Glocal University Pharmacy college, Glocal University, Delhi-Yamunotri Marg, State Highway-57, Mirzapur Pole, Distt. Saharanpur-247122(U.P.)
[2]Hari College of Pharmacy, Malhipur Road, Village -Jendheri Saharanpur 247001 (U.P.).
3 Bharat Institute of Technology Partapur Bypass Meerut 250001 (U.P.).
***Corresponding Author:** Umesh Kumar
*Glocal University Pharmacy college, Glocal University, Delhi-Yamunotri Marg, State Highway-57, Mirzapur Pole, Distt. Saharanpur-247122(U.P.)

Citation: Umesh Kumar, et al (2024), A Comprehensive Review: Molecular Target And Procurable Treatment For Rheumatoid Arthritis, *Educational Administration: Theory and Practice, 30(2),* 1364-1372
Doi: 10.53555/kuey.v30i2.6954

ARTICLE INFO

ABSTRACT

Recently licensed synthetic small-molecule-focused anti-rheumatism that adapts to sickness medication is called Tofacitinib. The medication was created to block pro-inflammatory receptor signaling in a precise and selective manner. By blocking the Janus kinases, Tofacitinib limits Inflammation is a distinct process that biological medicines cannot address. Patients with medium-to-serious active Rheumatoid Arthritis now have the option of receiving therapy with Tofacitinib. Numerous clinical studies have demonstrated tofacitinib's effectiveness. The drug stops the radiographic evolution of the illness. One noteworthy aspect of tofacitinib's new mechanism of action is that it offers patients who do not respond to current treatments hope for a successful course of treatment. Rheumatoid arthritis (RA) is a chronic inflammatory disorder that primarily affects joints. The molecular targets for the treatment of RA aim to reduce inflammation, halt disease progression, and manage symptoms these include Tumour Necrosis Factor-alpha (TNF-α), Interleukin-6 (IL-6), Interleukin-1 (IL-1), Interleukin-1 (IL-1), T-cell Co-stimulation. B-cell Depletion, Interleukin-17 (IL-17), Granulocyte-macrophage colony-stimulating factor (GM-CSF), HLA-DRB1, PTPN22, STAT4, PADI4, IL2RA, CTLA4, IRAK1, TNFAIP3, BLK, Potential Therapeutic Approaches, Gene Therapy: Modifying expression or correcting mutations in these genes., Targeted Drugs: Developing drugs that specifically modulate the activity of proteins encoded by these genes, designing biologic agents that interact with the gene products involved in RA pathogenesis.

Keywords: Tofacitinib, Rheumatoid Arthritis, Tumour Necrosis Factor-alpha,), Interleukin-1, B-cell Depletion

1.Introduction:

Rheumatoid arthritis (RA) is a chronic systemic inflammatory illness that is autoimmune-based. The etiology of RA is unknown. Treatment approaches for RA have advanced significantly in the last 20 years. The advent of biological drugs, the improvement of general treatment principles, and the creation of therapeutic techniques have all made this feasible. For individuals with RA, however, medicine is the cornerstone of an incomplete treatment plan [1]. It has been shown that DMARDs, or disease-modifying anti-rheumatic medications, prevent the deterioration of structural joints. The evaluation of disease activity serves as the foundation for determining remission with a high degree of likelihood. To measure the severity of the condition, composite disease activity indexes are employed. These indexes are not covered in this study; a description of them may be obtained in handbooks. The main causes are the therapy's primary or secondary inefficiency, as well as the patient's eventual development of intolerance. Additionally, the patient's attitude (disregard, haphazard dosage reduction, etc.) can be connected to it [5, 6]. Since protein molecules make up biological medications, their immunogenicity may lessen the therapeutic impact [7]. Moreover, a patient may experience a distinct course of their illness. For example, some people develop "aggressive" inflammation,

which worsens quickly and is poorly treated. For instance, up to 70% of RA patients do not achieve the intended therapeutic objective while using conventional synthetic DMARDs [8]. About 25% of patients who stop taking methotrexate do so due to test abnormalities, whereas adverse reactions cause about 60% of these cases [9]. In 30–40% of cases, treatment does not lower disease activity as expected when biological drugs are used. [5,6]



Fig 1: Rheumatoid Arthritis

1.1 Mechanism of Action Disease-Modifying Anti-rheumatic Drugs

Synthetic medications work indirectly on the metabolic pathways that trigger the activation of the immune and inflammatory systems. There is still much to learn about these methods. By blocking the adenosine route, methotrexate, a purine antagonist, reduces inflammation and, to a lesser extent, prevents cell influx that damages joints structurally [14]. Pyrimidine antagonists include leflunomide and its active metabolite, teriflunomide [15, 16]. Because activated lymphocytes need pyrimidine synthesis to start with in order to divide, this prevents them from multiplying. There is no correlation between pyrimidine synthesis and the proliferation of non-activated lymphocytes. The other commonly used synthetic DMARDs have poorly understood mechanisms of action. Biological medications are "well-targeted" pain relievers. They locate in inflammatory cells, adhere to the relevant receptor's extracellular domain, and start the process of escalating the inflammation. For instance, certain biologics can inhibit sticky proteins or lower the quantity of immune-competent cells. Since all biological drugs are made of cells, they all function in the extracellular environment. They can only be administered parentally due to their protein composition.



Fig 2: Mechanism of Action Disease-Modifying Antirheumatic Drugs

1.2. Tofacitinib as a drug with different Mechanism of Action

Tofacitinib is a synthetic, tiny-Particles targeted anti-rheumatic drug that alters disease. Its main objective was to selectively and primarily block pro-inflammatory receptor signaling. Pro-inflammatory cytokines which bind to certain effector cell receptors' extracellular domain, as was previously proven. Intracellular receptor signal transmission ends in the cellular nucleus when transcription and specific gene expression occur. This leads to the de novo creation of many inflammatory proteins, such as pro-inflammatory cytokines and proteins, the induction of inflammatory angiogenesis, and so on. Intracellular signaling pathway gives biological medications an additional way to impede the inflammatory process. Signaling through receptors is a multi-step process. Consequently, the pair of Janus kinase molecules linked to the intracellular receptor domain becomes active. Phosphorylation alters the structure of proteins, which allows them to interact with other proteins that have the SH2 domain. (17) Dimers go to the nucleus of cells, where they start to express and transcribe certain genes required for elevated inflammatory activity [18]. TYK2 (tyrosine kinase 2), JAK1, JAK2, and JAK3 are the four Janus kinases that are now known to exist. The first meaning of "JAK" was "Just another Kinase." The enzymes indicated above are made up of two different domains: a kinase domain that catalyzes the process of phosphorylation and an inhibitory domain that stops it from happening [19]. Tofacitinib obstruct JAK1 and JAK3, which changes the signals from type I and II interferon receptors and interleukin and alters the inflammatory and immunological responses. Additional immunological pathways that may be involved in the pathophysiology of RA have been proposed [20]. In individuals with RA, tofacitinib dramatically lowers inflammation. Over the course of the six-month treatment period, this effect (a considerable drop in blood C-reactive protein levels) is evident as early as week two of medication. It persists after stopping the medication for at least two weeks [17]. RA patients on tofacitinib exhibited lower levels of circulating CD16/56+ NK cells. [17]. Furthermore, the medication raises the B-cell count while having no effect on the quantity or subpopulations of T cells. Studies show that five years of tofacitinib use results in a 25% reduction in CD4 and CD8 cell counts. There's no evidence linking these alterations to infection rates. The levels of total serum immunoglobulin G, M, or A were unaffected by dacatinib treatment [17]. On the other hand, patient compliance could affect how successful it is. As a result, the drug's special extended-release (ER) formulation was created. (19)

1.3. Tofacitinib in the treatment of Patients with Rheumatoid Arthritis

Oral tofacitinib 5 mg twice daily may be beneficial for adult patients in the European Union with clinical studies such as ORAL SOLO and ORAL SYNC have shown that tofacitinib is well tolerated either on its own or in combination with other cs DMARDs such as methotrexate [22, 23].



Fig 4: Tofacitinib in the treatment of Patients with Rheumatoid Arthritis

2. Efficacy of Monotherapy

The drug stops the radiographic evolution of the sickness. The second week of treatment was when the first effects (ACR20) were noticeable. The combination of tofacitinib and methotrexate has not been demonstrated to be a less effective oral treatment than adalimumab plus methotrexate. The subjects were systematically to either 5 mg or 10 mg of Tofacitinib for duration of three months. Following that, for a further three months, they received either a placebo or 10 mg of Tofacitinib. Primary aim ($p < 0.001$). 4.4%, 8.7%, and 5.6% of the population, respectively, had a DAS28-ESR < 2.6. The quality of life changed by -0.50 and -0.57 vs. -0.19 ($p < 0.001$), according to the HAQ-DI score.

2.1. Efficacy of Combination Treatment

ORAL SYNC searched the use of Tofacitinib in individuals with Rheumatoid Arthritis who either did not respond adequately to biologics such as TNF-α antagonist or did not react to DMARDs (methotrexate and other csDMARDs). Compared to 2.6% in the placebo group, 8.5% and 12.5% of the individuals, respectively, had remission after six months. [26].

2.2. Inhibition of structural damage progression

Investigating the level of resist of radiographic disease increament in individuals who did not react well to methotrexate was the aim of the oral scan. It was evaluated for tofacitinib doses of 5 mg and 10 mg in conjunction along MTX. Tofa-citinib has been demonstrated in the study to slow the advancement in body joint deterioration and to reduce disease action [27]. The goal of having tofacitinib-treated participants exhibit a higher suppression of radiographic progression in comparison to control subjects was not met. The

prolonged duration of the disease and the early onset of radiographic abnormalities may have contributed to the little structural damage advancement in both groups.

2.3. Efficacy after failure the conventional synthetic Disease-Modifying Antirheumatic drugs

Randomly assigned to groups receiving tofacitinib were those in the placebo group who, by the third month, did not show a 20% drop in the number of swollen or sensitive joints. In the sixth month, adalimumab (47.2%), Tofacitinib (5 mg or 10 mg), and both had higher ACR20 rates than placebo (28.3%) [28]. In sick people who didn't give respond well to csDMARDs. Phase IIIb/IV, double-blind, 12-month trial. Following a six-month period, 39% of participants in the I group, 47% in the II group, and 45% in the adalimumab group had achieved ACR50. The experiment found that the combination of tofacitinib and methotrexate did not perform worse than the combination of methotrexate and adalimumab [26].

2.4. Efficacy after failure of biological Treatment

Examining the effectiveness of Tofacitinib in conjunction with methotrexate for sick person who had not acknowledged to biological therapy with TNF-α inhibitors was the goal of the six-month ORAL STEP trial. The study involved more than four hundred individuals. In individuals receiving tofacitinib at a higher dosage at month three, 48% (64/133) achieved ACR20, as did 41.7% of participants take tofacitinib 5 mg bid (56/133). 24.4% (32/131) of the methotrexate-treated patients reached ACR20. In 1.7%, 6.7%, and 8.8% of cases, DAS28 was less than 2.6. With 4% of patients experiencing each, headache, nasopharyngitis, and diarrhea were the most adverse effects. The study verified that in patients who didn't give respond to biological therapy with TNF-α inhibitors, Tofacitinib helped to create an early and excellent clinical response [28]. However, only a tiny percentage of the patients in this cohort achieved clinical remission following such a brief course of treatment.

2.5 Sustained Therapeutic Effects

Extended safety investigations validate both the safety profile demonstrated in significant clinical trials and the ongoing effectiveness of tofacitinib. A study of 6194 tofacitinib-treated patients was reported by Cohen et al. (2017) [29]. The outcomes of a different trial that evaluated tofacitinib's use in clinical practices over a three-year period were released to the public in February 2018 [29]. 34,223 patient-years, or 9291 patients, were included in the investigation. There didn't seem any changes to the medication's extended-term safety profile or variations in safety between clinical practices and research.



Diagram 5. Efficacy after failure of conventional syntjhetic Disease-Modifying Antirheumatic drugs

3. The Role of Tofacitinib in Current Strategies

The American College of Rheumatology (ACR) altered its algorithm in 2015 [2] [31] The guidelines stress the necessity of using methotrexate, the significance of promptly identifying rheumatoid arthritis, and the use of sulfasalazine or leflunomide in circumstances in which methotrexate is not suitable.

If the medications employed in the first phase are not tolerated, a similar strategy is needed. One should be aware of any signs that the disease is progressing "aggressively" and quickly in order to begin the second

stage of therapy. Something similar is treated with a biological medication, and methotrexate is typically maintained if well tolerated.
It can be used as a stand-alone medication or in combination with methotrexate. Like all previous stages, the aim of this therapy phase is to attain low disease activity or remission before the scheduled six-month mark. If the therapeutic aim is not reached, one should use a Janus kinase inhibitor or another biological drug. 2015 saw the introduction of the ACR treatment recommendations, one year earlier.

3.1 Tofacitinib Registry Observations

A number of registries, including the Swiss registry, the American Corona registry, and data from clinical trials, provided information on tofacitinib, which was gathered and examined.
670 rheumatologists from 170 sites around the US provide data to the registry. The Corona Registry has information on about 45,500 sick people and more than 153,000 patient years as of June 30, 2017. The US is seeing an increase in the number of patients collects Tofacitinib, and the demographic makeup of these individuals is similar to that of patients beginning biological therapy, according to the most recent figures available. It is more typical to use Tofacitinib in monotherapy.

3.2 Safety Profile of Tofacitinib

The Defense profile of tofacitinib was evaluated in both published clinical studies and real-world scenarios.
At the ACR 2017 conference, analyses of tofacitinib use over a ten-year period were presented. Their results supported information that had previously been gleaned from clinical research [30]. The safety profile uncovered in clinical studies was most significantly verified by clinical practice. Based on data from the US Corona Registry, the danger of TB, gastrointestinal perforation, cardiovascular events, neoplasms, and severe infections is similar to that of biological therapy. [37]
The prevalence of Tofacitinib in herpes zoster infection cases was only marginally higher; however, the effect varied by geography, with the lowest risk observed in Central and Eastern Europe and the highest risk in Asia (Japan) . Moreover, over 90% of the cases involved only one dermatome, and the majorities (about 90%) were simple, moderate instances. Just 8% of patients had to stop taking tofacitinib entirely, 40% had to stop taking it for a brief period of time, and 40% were still required to take it. The majority of patients did not need to stop using it. [39]

3.3 Childhood Side Effects

Adults and children experience Tofacitinib side effects differently in terms of frequency and kind. In one trial, minor side effects were observed in 37% of patients receiving Tofacitinib during a 24-week period. Over the course of the following twenty-four weeks, the majority of these side effects subsided after appearing during the first six weeks of therapy [21]. Other adverse effects that were seen during the first six weeks were headaches and increased alanine transaminase, both of which improved in the weeks that followed. One negative effect that has been reported in several trials is anemia. Its frequency rose throughout the first twenty-four weeks, from 3.7% at week six to 7.4% at week twenty-four.
From 3.7% at week six to 7.4% at week twenty-four, its frequency increased throughout the course of the first twenty-four weeks [21, 22]. At the conclusion of the study, unresolved viral infections showed a customary moderate negative impact [22]. Compared to adult patients, children who get long-term Tofacitinib treatment experience fewer, milder side effects, many of which go away with time.

3.4 Adults Side Effects

Over 25% of people using tofacitinib for more than nine years' experience major adverse effects, according to several research; one study found that 23.1% of patients stopped their therapy as a result of these side effects [18, 19].
Infection is the most frequent side effect for both little-dose (5 mg) and more amount-dose (10 mg) tofacitinib; studies show that over 67% of patients had at least one infection while receiving therapy [18].

4. Interaction between Tofacitinib and different other Drugs

Co-administration of the CYP inducer rifampicin with Tofacitinib may result in a decrease in its concentration. This is particularly important for people with latent tuberculosis who received anti-mycobacteria treatment before beginning Tofacitinib. If Tofacitinib is started when rifampicin is being delivered, then the lesser effectiveness of the normal dosage should be taken into contemplation. As isoniazid and Tofacitinib do not interact, this statement does not apply to combination therapies. It is crucial to emphasize that there is no evidence of methotrexate affecting the therapeutic levels of tofacitinib pharmacokinetics. Similarly, Tofacitinib had no action on the drug movement of metformin .[17]
Chronic use of nephrotoxic drugs, such as methotrexate and NSAIDs, can cause renal failure in RA patients. Research by Bae SH et al. showed that animals with renal failure had a much larger area under the drug metabolism curve than control rats. [17]

Conclusions

A new era of therapeutic choices has been made possible with the information of Tofacitinib for the therapy of individuals with RA. According to research from 2014 and 2015, when traditional synthetic therapeutic ameliorating. anti-rheumatic medication(s) prove ineffective or unacceptable, tofacitinib should be started as part of the treatment plan.

The study data that are now accessible fully corroborate the reasoning behind the previously given suggestion. These findings also suggest that the treatment's approved indications may be increased and that it could be useful in the future for treating other illnesses.

Because of its exceptional method of action, tofacitinib offers patients who don't respond well to other drugs a shot at effective therapy. The mode of administration is particularly important since it is an additional feature that distinguishes the medication from biological therapy.

References:

1. Alten, R., Krüger, K., Rellecke, J., Schiffner-Rohe, J., Behmer, O., Schiffhorst, G., & Nolting, H.-D. (2016, November). Examining patient preferences in the treatment of rheumatoid arthritis using a discrete-choice approach. *Patient Preference and Adherence, Volume 10*, 2217-2228. doi:10.2147/ppa.s117774
2. Bartelds, G., Chlm, K., & Nurmohamed, M. (2011, April 13). Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up. *JAMA, 305*, 1460. doi:10.1001/jama.2011.406
3. Bartosińska, J., Zakrzewska, E., Król, A., Raczkiewicz, D., Purkot, J., Majdan, M., . . . Giannopoulos, K. (2017, November 3). Differential expression of programmed death 1 (PD-1) on CD4+ and CD8+ T cells in rheumatoid arthritis and psoriatic arthritis. *Polish Archives of Internal Medicine, 127*, 815–822. doi:10.20452/pamw.4137
4. Burmester, G., Blanco, R., Charles-Schoeman, C., Wollenhaupt, J., Zerbini, C., Benda, B., . . . Mebus, C. (2013, February). Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. *The Lancet, 381*, 451-460. doi:10.1016/s0140-6736(12)61424-x
5. Cohen, S., Curtis, J., & Demasi, R. (2018, February 22). Worldwide, 3-year, post-marketing surveillance experience with tofacitinib in rheumatoid arthritis. *Rheumatol Ther*. doi:10.1007/s40744-018-0097-3.
6. Cohen, S., Tanaka, Y., Mariette, X., Curtis, J., Lee, E., Nash, P., . . . Wollenhaupt, J. (2017, January 31). Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. *Annals of the Rheumatic Diseases, 76*, 1253-1262. doi:10.1136/annrheumdis-2016-210457
7. Dikranian, A., Gonzalez-Gay, M., Wellborne, F., Alvaro-Gracia, J., Takiya, L., Stockert, L., . . . Curtis, J. (2017). SAT0127 The efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index. In *Saturday, 16 JUNE 2018* (Vol. 69, p. 20). BMJ Publishing Group Ltd and European League Against Rheumatism. doi:10.1136/annrheumdis-2018-eular.1284
8. Fleischmann, R. (2018). Tofacitinib in the Treatment of Active Rheumatoid Arthritis in Adults. *Immunotherapy, 10*, 39-56. doi:10.2217/imt-2017-0118
9. Fleischmann, R., Kremer, J., Cush, J., Schulze-Koops, H., Connell, C., Bradley, J., . . . Kanik, K. (2012, August 9). Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis. *New England Journal of Medicine, 367*, 495-507. doi:10.1056/nejmoa1109071
10. Fleischmann, R., Mysler, E., & Hall, S. (2017). Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexatein patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomized controlled trial. *Lancet, 390*, 457–468.
11. Fragoso, Y., & Brooks, J. (2015, February 24). Leflunomide and teriflunomide: altering the metabolism of pyrimidines for the treatment of autoimmune diseases. *Expert Review of Clinical Pharmacology, 8*, 315-320. doi:10.1586/17512433.2015.1019343
12. Garcês, S., Demengeot, J., & Benito-Garcia, E. (2013). The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. *Annals of the Rheumatic Diseases, 72*, 1947-1955. doi:10.1136/annrheumdis-2012-202220
13. Goodman, S., Springer, B., Chen, A., Davis, M., Fernandez, D., Figgie, M., . . . Singh, J. (2017). 2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty. *The Journal of Arthroplasty, 37*, 1676-1683. doi:10.1016/j.arth.2022.05.043
14. Harnett, J., Gerber, R., Gruben, D., Koenig, A., & Chen, C. (2016, December). Evaluation of Real-World Experience with Tofacitinib Compared with Adalimumab, Etanercept, and Abatacept in RA Patients with 1 Previous Biologic DMARD: Data from a U.S. Administrative Claims Database. *Journal of Managed Care & Specialty Pharmacy, 22*, 1457-1471. doi:10.18553/jmcp.2016.22.12.1457

15. Iwamoto, N., Tsuji, S., & Takatani, A. (2017). Efficacy and safety at 24 weeks of daily clinical use of tofacitinib in patients with rheumatoid arthritis. *PLoS ONE, 12*.
16. Jiang, J.-K., Ghoreschi, K., Deflorian, F., Chen, Z., Perreira, M., Pesu, M., . . . Thomas, C. (2008, November 19). Examining the Chirality, Conformation and Selective Kinase Inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550). *Journal of Medicinal Chemistry, 51*, 8012-8018. doi:10.1021/jm801142b
17. Kremer, J., Li, Z., & Hall, S. (2013). Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. *Ann Intern Med, 159*, 253–261.
18. Kucharz, E. (2001). Zastosowanie leflunomidu w leczeniu chorych na reumatoidalne zapalenie stawów. *Pol Arch Med Wewn, 105*, 177–182.
19. Kucharz, E. (2017, December 1). MEDICAL EPONYMS OF MYTHOLOGICAL ORIGIN. *Acta Neophilologica, 2*, 29-42. doi:10.31648/an.639
20. Kucharz, E., Smolen, J., Van Der Heijde, D., & Machold, K. (1999). Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexatein patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomized controlled trial. (T. 36. Mimori, M. Harigai, T. Atsumi, & et al., Eds.) *Expert Rev Clin Pharmacol, 73*, 1460–1468. doi:10.1007/s40744-018-0097-3.
21. Kucharz, E., Stajszczyk, M., & Batko, B. (2017). How compare biologics applied for rheumatic disorders? *Rheumatology, 52*, 112-119. doi:10.5114/reum.2014.42796
22. Lee, Y., & Song, G. (2014). Relative Remission and Low Disease Activity Rates of Tofacitinib, Baricitinib, Upadacitinib, and Filgotinib versus Methotrexate in Patients with Disease-Modifying Antirheumatic Drug-Naive Rheumatoid Arthritis. *Pharmacology, 108*, 589-598. doi:10.1159/000527186
23. Lipsky, P., Van Der Heijde, D., Clair, S., & E. (2000). Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. *N Engl J Med, 343*, 1594–1602.
24. Louder, A., Singh, A., & Saverno, K. (2016). Patient preferences regarding rheumatoid arthritis therapies: a conjoint analysis. *Am Health Drug Benefits, 9*, 84–93.
25. Marzioli, V., Canavan, M., & Wade, S. (2018). Tofacitinib impairs monocyte-derived dendritic cell differentiation in rheumatoid arthritis and psoriatic arthritis. *Ann Rheum Dis, 77*.
26. Mease, P., Kremer, J., Cohen, S., Curtis, J., Charles-Schoeman, C., Loftus, E., . . . Jones, T. (2017). SAT0243 Incidence of thromboembolic events in the tofacitinib rheumatoid arthritis, psoriasis, psoriatic arthritis and ulcerative colitis development programmes. In *Saturday, 16 JUNE 2018* (Vol. 69). BMJ Publishing Group Ltd and European League Against Rheumatism. doi:10.1136/annrheumdis-2018-eular.3048
27. Mimori, T., Harigai, M., & Atsumi, T. (2017). Post-marketing surveillance of tofacitinib in Japanese patients with rheumatoid arthritis: an interim report of safety data [abstract] Arthritis Rheumatol. *Post-marketing surveillance of tofacitinib in Japanese patients with rheumatoid arthritis: an interim report of safety data [abstract] Arthritis Rheumatol, 69*. Google Scholar.
28. Nikiphorou, E., Negoescu, A., Fitzpatrick, J., Goudie, C., Badcock, A., Östör, A., & Malaviya, A. (2014, March 9). Indispensable or intolerable? Methotrexate in patients with rheumatoid and psoriatic arthritis: a retrospective review of discontinuation rates from a large UK cohort. *Clinical Rheumatology, 33*, 609-614. doi:10.1007/s10067-014-2546-x
29. Ogdie, A., De Vlam, K., Mcinnes, I., Mease, P., Baer, P., Lukic, T., . . . Maniccia, A. (2017). SAT0221 Effect of tofacitinib on reducing pain in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. In *Saturday, 16 JUNE 2018* (Vol. 69). BMJ Publishing Group Ltd and European League Against Rheumatism. doi:10.1136/annrheumdis-2018-eular.3247
30. Rubbert-Roth, A., & Finckh, A. (2009). Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. *Arthritis Research & Therapy, 11*, S1. doi:10.1186/ar2666
31. Schneeberger, E., Salas, A., Medina, L., Zacariaz, J., Mantilla, R., Sarmiento-Monroy, J., . . . Leon, D. (2017, June). AB0419 Real world use of tofacitinib in rheumatoid arthritis: data from latin america. In *Abstracts Accepted for Publication* (Vol. 76). BMJ Publishing Group Ltd and European League Against Rheumatism. doi:10.1136/annrheumdis-2017-eular.1607
32. Singh, J., Saag, K., Bridges, S., & Jr. (2015). American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. *Arthritis Care Res, 68*, 1–25.
33. Smolen, J., Landewé, R., & Bijlsma, J. (2017). EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. *Ann Rheum Dis, 76*, 960–977.
34. Smolen, J., Van Der Heijde, D., Machold, K., Aletaha, D., & Landewé, R. (2014). Proposal for a new nomenclature of disease-modifying antirheumatic drugs: Table 1. *Annals of the Rheumatic Diseases, 73*, 3-5. doi:10.1136/annrheumdis-2013-204317

35. St. Clair, E., Van Der Heijde, D., Smolen, J., Maini, R., Bathon, J., Emery, P., . . . Baker, D. (2004, November). Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial. *Arthritis & Rheumatism, 50*, 3432-3443. doi:10.1002/art.20568
36. Strand, V., Ahadieh, S., French, J., Geier, J., Krishnaswami, S., Menon, S., . . . Gómez-Reino, J. (2015, December). Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials. *Arthritis Research & Therapy, 17*, 362–367. doi:10.1186/s13075-015-0880-2
37. Tarp, S., Eric Furst, D., Boers, M., Luta, G., Bliddal, H., Tarp, U., . . . Christensen, R. (2017). Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis. *Rheumatology, 56*, kew442. doi:10.1093/rheumatology/kew442
38. Taylor, P., Sullivan, E., & Wood, R. (2015). Factors influencing treatment adjustments in rheumatoid arthritis patients - biologic DMARD treatment start and options. *Arthritis Rheumatol, 67*.
39. Tian, G., & Li, Z. (2007). Research Progress of Chinese and Western Medicine in Treatment of Rheumatoid Arthritis. *Journal of Innovations in Medical Research, 2*, 11-18. doi:10.56397/jimr/2023.01.03
40. Tofacitinib. (n.d.). In *Summary of Product Characteristics*.
41. Van Der Heijde, D., Tanaka, Y., Fleischmann, R., Keystone, E., Kremer, J., Zerbini, C., . . . Connell, C. (2013, February 25). Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four–month phase III randomized radiographic study. *Arthritis & Rheumatism, 65*, 559-570. doi:10.1002/art.37816
42. Van Vollenhoven, R., Fleischmann, R., & Cohen, S. (2012). Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. *N Engl J Med, 367*, 508–519.
43. Van Vollenhoven, R., Geborek, P., Forslind, K., Albertsson, K., Ernestam, S., Petersson, I., . . . Bratt, J. (2012, May). Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. *The Lancet, 379*, 1712-1720. doi:10.1016/s0140-6736(12)60027-0
44. Weinblatt, M., Keystone, E., Furst, D., Moreland, L., Weisman, M., Birbara, C., . . . Chartash, E. (2003, January). Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. *Arthritis & Rheumatism, 48*, 35-45. doi:10.1002/art.10697
45. Weinblatt, M., Kremer, J., Bankhurst, A., Bulpitt, K., Fleischmann, R., Fox, R., . . . Burge, D. (1999, January 28). A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving Methotrexate. *New England Journal of Medicine, 340*, 253-259. doi:10.1056/nejm199901283400401
46. Winthrop, K., Curtis, J., Lindsey, S., Tanaka, Y., Yamaoka, K., Valdez, H., . . . Bananis, E. (1960). Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy. *Arthritis & Rheumatology, 69*, 1960-1968. doi:10.1002/art.40189
47. Winthrop, K., Silverfield, J., & Racewicz, A. (2016). The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis. *Ann Rheum Dis, 75*, 687–695.
48. Wollenhaupt, J., Silverfield, J., Lee, E., Terry, K., Kwok, K., Strengholt, S., . . . Wang, L. (2017). SAT0234 Tofacitinib, an oral janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in open-label, long-term extension studies over 9 years. In *Saturday, 16 JUNE 2018* (Vol. 69). BMJ Publishing Group Ltd and European League Against Rheumatism. doi:10.1136/annrheumdis-2018-eular.1733